Publikationen, an denen er mitarbeitet Manuel Vicente Sánchez Chapado (28)

2016

  1. Anti-proliferative and pro-apoptotic effects of GHRH antagonists in prostate cancer

    Oncotarget, Vol. 7, Núm. 32, pp. 52195-52206

2015

  1. VIP induces NF-κB1-nuclear localisation through different signalling pathways in human tumour and non-tumour prostate cells

    Cellular Signalling, Vol. 27, Núm. 2, pp. 236-244

2014

  1. Signalling pathways involved in antitumoral effects of VIP in human renal cell carcinoma A498 cells: VIP induction of p53 expression

    International Journal of Biochemistry and Cell Biology, Vol. 53, pp. 295-301

2013

  1. Antitumoral effects of vasoactive intestinal peptide in human renal cell carcinoma xenografts in athymic nude mice

    Cancer Letters, Vol. 336, Núm. 1, pp. 196-203

  2. Vasoactive intestinal peptide induces oxidative stress and suppresses metastatic potential in human clear cell renal cell carcinoma

    Molecular and Cellular Endocrinology, Vol. 365, Núm. 2, pp. 212-222

2012

  1. Antioxidant activity of vasoactive intestinal peptide in HK2 human renal cells

    Peptides, Vol. 38, Núm. 2, pp. 275-281

  2. Overexpression of vasoactive intestinal peptide receptors and cyclooxygenase-2 in human prostate cancer. Analysis of potential prognostic relevance

    Histology and Histopathology, Vol. 27, Núm. 8, pp. 1093-1101

  3. Vasoactive intestinal peptide (VIP) inhibits human renal cell carcinoma proliferation

    Biochimica et Biophysica Acta - Molecular Cell Research, Vol. 1823, Núm. 10, pp. 1676-1685

2010

  1. Regulation of HER expression and transactivation in human prostate cancer cells by a targeted cytotoxic bombesin analog (AN-215) and a bombesin antagonist (RC-3095)

    International Journal of Cancer, Vol. 127, Núm. 8, pp. 1813-1822

  2. Vasoactive intestinal peptide (VIP) induces malignant transformation of the human prostate epithelial cell line RWPE-1

    Cancer Letters, Vol. 299, Núm. 1, pp. 11-21

2009

  1. Multifunctional role of VIP in prostate cancer progression in a xenograft model: Suppression by curcumin and COX-2 inhibitor NS-398

    Peptides, Vol. 30, Núm. 12, pp. 2357-2364

  2. Vasoactive intestinal peptide behaves as a pro-metastatic factor in human prostate cancer cells

    Prostate, Vol. 69, Núm. 7, pp. 774-786

2007

  1. Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer: Antagonistic action of an analog of growth-hormone-releasing hormone

    International Journal of Oncology, Vol. 31, Núm. 5, pp. 1223-1230

  2. Vasoactive intestinal peptide induces cyclooxygenase-2 expression through nuclear factor-κB in human prostate cell lines. Differential time-dependent responses in cancer progression

    Molecular and Cellular Endocrinology, Vol. 270, Núm. 1-2, pp. 8-16

2006

  1. Hypoxia regulation of expression and angiogenic effects of vasoactive intestinal peptide (VIP) and VIP receptors in LNCaP prostate cancer cells

    Molecular and Cellular Endocrinology, Vol. 249, Núm. 1-2, pp. 116-122

2005

  1. Expression of vasoactive intestinal peptide and functional VIP receptors in human prostate cancer: antagonistic action of a growth-hormone-releasing hormone analog.

    International journal of oncology, Vol. 26, Núm. 6, pp. 1629-1635

  2. Importancia de las proteínas G heterotriméricas en la biología molecular del cancer de próstata

    Actas Urologicas Espanolas, Vol. 29, Núm. 10, pp. 948-954

2004

  1. Effects of the antiandrogen flutamide on the expression of protein kinase C isoenzymes in LNCaP and PC3 human prostate cancer cells

    Bioscience Reports, Vol. 24, Núm. 1, pp. 11-21

2003

  1. Expression of functional PACAP/VIP receptors in human prostate cancer and healthy tissue

    Peptides, Vol. 24, Núm. 6, pp. 893-902

  2. Expression of functionally active cannabinoid receptor CB1 in the human prostate gland

    Prostate, Vol. 54, Núm. 2, pp. 95-102